Hyperekplexia is a neurological disorder associated primarily with mutations in the ␣1 subunit of glycine receptors (GlyRs) that lead to dysfunction of glycinergic inhibitory transmission. To date, most of the identified mutations result in disruption of surface expression or altered channel properties of ␣1-containing GlyRs. Little evidence has emerged to support an involvement of allosteric GlyR modulation in human hyperekplexia. Here, we report that recombinant human GlyRs containing ␣1 or ␣1␤ subunits with a missense mutation in the ␣1 subunit (W170S), previously identified from familial hyperekplexia, caused remarkably reduced potentiation and enhanced inhibition by Zn 2ϩ . Interestingly, mutant ␣1 W170S ␤ GlyRs displayed no significant changes in potency or maximum response to glycine, taurine, or ␤-alanine. By temporally separating the potentiating and the inhibitory effects of Zn 2ϩ , we found that the enhancement of Zn 2ϩ inhibition resulted from a loss of Zn 2ϩ -mediated potentiation. The W170S mutation on the background of H107N, which was previously reported to selectively disrupt Zn 2ϩ inhibition, showed remarkable attenuation of Zn 2ϩ -mediated potentiation and thus indicated that W170 is an important residue for the Zn 2ϩ -mediated GlyR potentiation. Moreover, overexpressing the ␣1 W170S subunit in cultured rat neurons confirmed the results from heterologous expression. Together, our results reveal a new zinc potentiation site on ␣1 GlyRs and a strong link between Zn 2ϩ modulation and human disease.
Introduction
Hyperekplexia is an inherited neuronal disorder characterized by hypertonia and exaggerated startle reflex to unexpected sensory stimuli (Bakker et al., 2006) . Hyperekplexia is caused by dysfunction of glycinergic transmission that can result from diverse root causes that include loss of function of glycine receptors (GlyRs), reduced receptor clustering of GlyRs at synapses, or reduced glycine release from presynaptic terminals (Harvey et al., 2008) . Most cases of identified familial hyperekplexia are associated with dominant or recessive missense mutations of the glra1 gene, which encodes the ␣1 subunit of GlyRs (Lynch, 2004) . These mutations commonly lead to severe impairments of ␣1 GlyRmediated synaptic inhibition either by reducing surface expression of synaptic GlyRs or by disrupting basic channel properties, such as agonist binding affinity, channel gating, and channel conductance (Chung et al., 2010) . Complete loss of function mutations of ␣1 subunit has also been reported, causing hyperekplexia symptoms that are clinically indistinguishable from patients carrying missense glra1 mutations (Brune et al., 1996) . However, in animal models, deletion of functional ␣1 subunits caused more severe symptoms and juvenile death in mutant mice, suggesting that deficits in human ␣1 subunit might be more efficiently compensated (Buckwalter et al., 1994) .
GlyRs are activated by multiple endogenous agonists, including glycine, ␤-alanine, and taurine. In addition, GlyRs also exhibit significant allosteric modulation by various effectors, such as Zn 2ϩ , endocannabinoids, steroids, and alcohols (Lynch, 2004) . Among these allosteric modulators, Zn 2ϩ is enriched in presynaptic vesicles in many regions of the CNS and acts as a potent allosteric modulator of inhibitory GlyRs (Sensi et al., 2011) . Low concentrations (Ͻ10 M) of Zn 2ϩ potentiate GlyR currents, whereas high concentrations (Ͼ10 M) inhibit GlyRmediated responses (Bloomenthal et al., 1994; Laube et al., 1995) . Before this study, there has been no evidence from reported human mutations that hyperekplexia is caused by impaired allosteric modulation without affecting basic receptor properties of GlyRs. Although selectively removing sensitivity to Zn 2ϩ -mediated potentiation produced exaggerated startle reactions in knockin mice (Hirzel et al., 2006) , the different phenotype severities between human and murine glra1 null mutations make it difficult to predict whether simply disrupting Zn 2ϩ -mediated modulation of GlyRs also causes hyperekplexia in humans.
In this study, we report that the missense mutation W170S in the GlyR ␣1 subunit, which was recently identified from Omani families with hyperekplexia and mild mental retardation (AlFutaisi et al., 2012), caused almost complete loss of Zn 2ϩ -mediated potentiation and enhancement of Zn 2ϩ -mediated inhibition. Unlike previously reported missense ␣1 mutations from human cases of hyperekplexia, ␣1 W170S -containing GlyRs displayed no significant alterations in agonist sensitivities, maximal current responses, or current-voltage (I-V) relations. The major alteration of ␣1 W170S was the ablated sensitivity to Zn 2ϩ -mediated potentiation, which was determined in both a recombinant expression system and in cultured neurons. Collectively, our findings demonstrate that impaired allosteric modulation of ␣1 GlyRs by Zn 2ϩ may directly lead to human hyperekplexia.
Materials and Methods
cDNA constructs and transfection. Wild-type (WT) human GlyR ␣1 (hGlra1) and the human GlyR ␤ subunit (hGlrb) were subcloned into the pBK-CMV NB-200 expression vector (Liu et al., 2010) . ␣1 W170S , ␣1 H107N , and ␣1 W170S/H107N plasmids were constructed by site-directed mutagenesis of hGlra1. The sequences of all the plasmids were confirmed by automated DNA sequencing. Purified plasmids encoding the WT or mutant GlyR ␣1 alone or with ␤ subunits (1:10; total plasmid amount 3-4.5 g) were transfected into HEK293T cells by electroporation (NEPA21, NEPA GENE). The ␣1 and ␣1␤ compositions of GlyRs were confirmed by their shifted sensitivity to picrotoxin using whole-cell patch-clamp recordings. A small amount (ϳ0.5 g) of pcDNA3-GFP was cotransfected along with GlyR subunits to act as a transfection marker and facilitate the visualization of transfected cells during electrophysiological experiments. Cells were replated on glass coverslips after transfection and cultured for an additional 15-24 h before patch-clamp recordings.
Neuronal culture and overexpression. Cultured cortical neurons were prepared from the neocortex of day 18 fetal rats (from embryos of either sex) as described previously (Liu et al., 2010) and were transiently transfected with ␣1 subunits (1 g) and GFP (0.3 g) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocols. Electrophysiological recordings were performed 3-7 d after plating.
Whole-cell patch-clamp recordings. Whole-cell recordings were performed under voltage-clamp mode using an Axopatch 200B (Molecular Devices). Whole-cell currents were recorded at a holding potential of Ϫ60 mV, and signals were low-pass filtered at 2 kHz and digitized at 10 kHz (Digidata, 1440A). Recording pipettes (3-5 M⍀) were filled with intracellular solution that contained the following (in mM): 140 CsCl, 10 HEPES, 4 Mg-ATP, and 0.5 BAPTA (pH 7.20, osmolarity, (290) (291) (292) (293) (294) (295) . The coverslips were continuously superfused with the extracellular solution containing the following (in mM): 140 NaCl, 5.4 KCl, 10 HEPES, 1.0 MgCl 2 , 1.3 CaCl 2 , and 20 glucose (pH 7.4, (305) (306) (307) (308) (309) (310) (311) (312) (313) (314) (315) . To evoke glycine currents, we used fast perfusion of glycine and other agonists with a computer-controlled multibarrel fast perfusion system (Warner Instruments). Maximum currents (I max ) were evoked by the highest concentration of the agonist as determined by the dose-response curves. Zn 2ϩ was applied both in the bath and together with the agonistcontaining solutions. All experiments were performed at 23-25°C.
Homology modeling. The mature hGlyR ␣1 subunit was modeled on the crystal structure of the glutamate-gated chloride channel ␣ (GluCl) (Hibbs and Gouaux, 2011) using I-TASSER server (Zhang, 2008; Roy et al., 2010 Roy et al., , 2012 . All 3D images were subsequently rendered using the UCSF Chimera package (Pettersen et al., 2004) .
Data analysis. Values are expressed as mean Ϯ SEM. One-way ANOVA or a two-tailed Student's t test was used for statistical analysis, and p values Ͻ0.05 were considered to be statistically significant. Doseresponse curves were created by fitting data to the Hill equation:
nH ], where I is the current, I max is the maximum current, [A] is a given concentration of agonist, and n H is the Hill coefficient.
Results
The startle disease mutation W170S did not alter heteromeric GlyR agonist sensitivities or channel permeability Glycine receptor-mediated currents were tested by whole-cell voltage-clamp recordings in HEK293T cells expressing WT or mutant GlyRs. Because the extracellular N terminus of ␣1 contains the GlyR agonist binding site and previously reported missense mutations at this region typically exhibit a feature of impaired sensitivity to agonist activation (Chung et al., 2010) , we first examined whether agonist binding affinities were altered in ␣1 W170S GlyRs. The dose-response curve of glycine-activated, homomeric ␣1 W170S GlyRs currents was shifted toward the right compared with homomeric ␣1
WT GlyRs, with the EC 50 increased from 62.9 Ϯ 5.0 M to 127.6 Ϯ 6.9 M (n H ϭ 3.38 Ϯ 0.49 and 1.69 Ϯ 0.14; n ϭ 5 and n ϭ 10, respectively; p Ͻ 0.05; Fig. 1A ). The agonist sensitivity of ␣1 W170S was also examined with the other two endogenous GlyR partial agonists, ␤-alanine and taurine. Homomeric ␣1 W170S showed increased sensitivity to activation by ␤-alanine (EC 50 ϭ 226.9 Ϯ 14.3 M and 99.4 Ϯ 8.0 M, n H ϭ 2.40 Ϯ 0.03 and 1.56 Ϯ 0.03, n ϭ 9 and n ϭ 9 in ␣1
WT and ␣1 W170S , respectively; p Ͻ 0.01; Fig. 1B ) and no change in sensitivity to activation by taurine (EC 50 ϭ 256.6 Ϯ 29.9 and 213.7 Ϯ 19.1 M, n H ϭ 1.55 Ϯ 0.05 and 1.57 Ϯ 0.04, n ϭ 8 and n ϭ 8, respectively; p Ͼ 0.05; Fig. 1C ). As the majority of ␣1-containing GlyRs in the adult CNS consist of heteromeric ␣1␤ GlyRs that may exhibit different current kinetics than homomeric receptors (Lynch, 2004) , we also investigated the potential for altered agonist sensitivities in heteromeric ␣1 W170S ␤ GlyRs. Interestingly, the ␣1 W170S ␤ receptors did not show significant impairment of the sensitivity to glycine (EC 50 ϭ 116.4 Ϯ 5.1 and 80.0 Ϯ 5.1 M, n H ϭ 2.45 Ϯ 0.02 and 1.96 Ϯ 0.03, n ϭ 5 and n ϭ 6 in ␣1
WT ␤ and ␣1 W170S ␤, respectively; p Ͼ 0.05; Fig. 1D ), ␤-alanine (EC 50 ϭ 91.0 Ϯ 7.6 and 95.5 Ϯ 8.0 M, n H ϭ 1.55 Ϯ 0.03 and 1.83 Ϯ 0.04, n ϭ 9 and n ϭ 8, respectively; p Ͼ 0.05; Fig. 1E ), or taurine (EC 50 ϭ 371.1 Ϯ 25.6 and 194.4 Ϯ 18.9 M, n H ϭ 1.60 Ϯ 0.03 and 1.45 Ϯ 0.04, n ϭ 8 and n ϭ 8, respectively; p Ͻ 0.05; Fig. 1F ). These data suggest that the hyperekplexia phenotype observed in humans carrying W170S alleles is not likely to be mediated by impaired agonist responsiveness of mutant GlyRs.
Missense mutations in other regions of ␣1 have been previously characterized that result in only moderate changes in GlyR agonist affinity yet also a remarkable reduction of maximal whole-cell currents (Saul et al., 1999) . We found that, in ␣1 W170S ␤ receptors, the maximal currents (I max ) evoked by saturating agonist concentrations, including 3 mM glycine (␣1 WT ␤, I max ϭ 9.4 Ϯ 1.2 nA, n ϭ 7; ␣1 W170S ␤, I max ϭ 7.5 Ϯ 0.9 nA, n ϭ 11; p Ͼ 0.05), ␤-alanine (␣1 WT ␤, I max ϭ 8.4 Ϯ 1.2 nA, n ϭ 7; ␣1 W170S ␤, I max ϭ 7.3 Ϯ 1.0 nA, n ϭ 11; p Ͼ 0.05), or 5 mM taurine (␣1 WT ␤, I max ϭ 7.3 Ϯ 1.4 nA, n ϭ 7; ␣1 W170S ␤, I max ϭ 6.6 Ϯ 0.9 nA, n ϭ 11; p Ͼ 0.05) were not significantly changed compared with the ␣1 WT ␤ receptors (Fig. 1G) . The I max induced by ␤-alanine (␣1 WT ␤, I ala /I gly ϭ 90.7 Ϯ 8.6%, n ϭ 7; ␣1 W170S ␤, I ala /I gly ϭ 95.7 Ϯ 4.5%, n ϭ 11; p Ͼ 0.05) or taurine (␣1 WT ␤, I tau /I gly ϭ 90.8 Ϯ 17.5%, n ϭ 7; ␣1 W170S ␤, I tau /I gly ϭ 85.8 Ϯ 5.2%, n ϭ 11; p Ͼ 0.05) as a percentage of the glycine-induced I max from the same cell was also indistinguishable between ␣1
WT ␤ and ␣1 W170S ␤ GlyRs (Fig. 1H ). In addition, the I-V relationship of 100 M glycine-induced responses in ␣1 W170S ␤ receptors showed no difference compared with ␣1
WT ␤ receptors, indicating that there were no changes in Cl Ϫ ion permeability ( Fig. 1 I, J ) . Together, these results suggest that the basic channel properties of recombinant ␣1 W170S ␤ GlyRs were not significantly different from that of ␣1 WT ␤ GlyRs.
Impaired Zn 2؉ -mediated modulation in ␣1
W170S -containing GlyRs To investigate how the W170S mutation affects glycine ␣1 receptors, we generated a homology model of ␣1 GlyR based upon the template of the crystal structure of glutamate-gated chloride channels, which share 45% identical and 62% positive sequences with the GlyR ␣1 subunit (Hibbs and Gouaux, 2011). The homology model showed that W170 was located at loop F in the outer face of the N terminus domain. It is structurally close to the previously reported Zn 2ϩ potentiation site (Miller et al., 2005b) , with particular proximity (Ͻ4 Å) to D194, a key residue for Zn 2ϩ binding ( Fig. 2A) . Therefore, we investigated the possibility that the W170S mutation might affect the sensitivity of GlyRs to Zn WT GlyRs (Fig. 2B top, C) . Interestingly, Zn 2ϩ -mediated potentiation of GlyRs was substantially attenuated in ␣1 W170S GlyRs (Fig. 2B, bottom; C, top) . Coexpression of the ␤ subunit did not rescue the deficit of Zn 2ϩ potentiation in ␣1 W170S , suggesting that the ablated Zn 2ϩ potentiation was preserved in ␣1 W170S ␤ GlyRs (Fig. 2C, bottom) . Zn 2ϩ potentiation of GlyR current responses evoked from partial agonists, such as taurine, might behave differently from the po- Figure 1 . The W170S mutation in ␣1␤ GlyRs showed no significant changes in agonist sensitivities, maximal current responses, or I-V relationship. A-C, Dose-response curves for ␣1
WT and ␣1 W170S homomeric GlyRs normalized to maximal currents induced by glycine (A), ␤-alanine (B), and taurine (C). D-F, Dose-response curves for ␣1 WT ␤ and ␣1 W170S ␤ heteromeric GlyRs normalized to maximal currents induced by glycine (D), ␤-alanine (E), and taurine (F ). G, Maximal responses (I max ) of glycine-, ␤-alanine-, and taurine-induced currents in ␣1
WT ␤ and ␣1 W170S ␤ GlyRs. H, The ␤-alanine-and taurine-mediated I max were normalized to glycine-mediated I max from the same cell. I, Representative traces of 100 M glycine-induced currents at different holding potentials from Ϫ60 mV to 60 mV. J, Peak I-V relations (normalized to the current recorded at Ϫ60 mV) of ␣1 WT ␤ and ␣1 W170S ␤ GlyRs. n.s., Not significant.
tentiation effect of glycine-evoked responses (Lynch et al., 1998 ). Therefore, we tested the effects of Zn 2ϩ on ␣1 W170S and ␣1
W170S
␤ GlyRs-mediated currents induced by ␤-alanine or taurine at EC 10 , respectively. We found that W170S similarly abolished Zn 2ϩ -mediated potentiation of responses induced by ␤-alanine or taurine in both homomeric and heteromeric receptors (Fig. 2D,E) . The Zn 2ϩ inhibition was also increased under these conditions, suggesting that W170S mutations cause either attenuated potentiation or enhanced inhibition of Zn 2ϩ in ␣1-containing GlyRs.
Altered Zn 2؉ modulation in W170S mutation was mainly the result of abolished potentiation At Zn 2ϩ concentrations ranging from 0.1 to 1000 M, the biphasic Zn 2ϩ -mediated modulation of ␣1 WT likely results from the superimposition of both positive and negative modulatory effects. Prior studies have shown that, if the GlyR has already been activated by the agonist, the positive and negative modulations of Zn 2ϩ can be temporally separated by showing an initial potentiation followed by prolonged inhibition of GlyR currents (Lynch et al., 1998) . By using this strategy, we further elucidated whether the altered responses of ␣1 W170S to Zn 2ϩ were the result of an ablation of Zn 2ϩ potentiation or an increase of Zn 2ϩ inhibition. In homomeric ␣1
WT receptors, after 30 M glycine was applied to induce a GlyR-mediated current, subsequent Zn 2ϩ application caused an initial potentiation at concentrations of 0.1 to 50 M (Fig. 3A) . The Zn 2ϩ -mediated inhibition became more apparent when Zn 2ϩ was washed out but glycine remained present (Lynch et al., 1998) . In ␣1 W170S GlyRs, however, the initial potentiation was completely absent (Fig. 3 B, C) , and the inhibition by Zn 2ϩ was consequently enhanced compared with ␣1
WT GlyRs (Fig.  3D ). These data demonstrated that Zn 2ϩ -mediated positive allosteric modulation was ablated in the ␣1 W170S . We further examined the effects of W170S on Zn 2ϩ -mediated potentiation by diminishing the influence of the inhibitory effects of Zn 2ϩ . The ␣1 mutation, H107N, has been reported to be at least 150-fold less sensitive than the ␣1
WT to Zn 2ϩ -mediated WT , n ϭ 7; ␣1 W170S , n ϭ 10) and heteromeric ␣1 W170S ␤ GlyRs (bottom; ␣1 WT , n ϭ 7; ␣1 W170S , n ϭ 10). D, Averaged Zn 2ϩ concentration-response curves for the modulation of EC 10 responses to ␤-alanine-activated currents in homomeric (top; ␣1 WT , n ϭ 5; ␣1 W170S , n ϭ 5) and heteromeric ␣1 W170S ␤ GlyRs (bottom; ␣1 WT , n ϭ 6; ␣1 W170S , n ϭ 5). E, Averaged Zn 2ϩ concentration-response curves for the modulation of EC 10 responses to taurine-activated currents in homomeric (top; ␣1 WT , n ϭ 5; ␣1 W170S , n ϭ 8) and heteromeric ␣1 W170S ␤ GlyRs (bottom; ␣1 WT , n ϭ 7; ␣1 W170S , n ϭ 5).
inhibition without significantly affecting Zn 2ϩ -mediated potentiation (Miller et al., 2005a, b) . Therefore, we generated the double-mutation ␣1 H107N/W170S on the background of ␣1
H107N
(␣1 H107N , EC 50 ϭ 41.6 Ϯ 3.1 M, n ϭ 2; ␣1 H107N/W170S , EC 50 ϭ 136.9 Ϯ 6.5 M, n ϭ 7). In ␣1 H107N GlyRs, Zn 2ϩ produced significant potentiation of glycine-induced responses without showing obvious inhibition at concentrations up to 100 M (Fig.  3 E, F ) . In contrast, Zn 2ϩ -mediated potentiation was abolished in ␣1 H107N/W170S receptors. At Zn 2ϩ concentrations of 50 -100 M, the W170S mutation even partially recovered the sensitivity of ␣1 H107N to Zn 2ϩ -mediated inhibition (Fig. 3F) . Together, these data revealed that W170 residue is likely a required site for Zn 2ϩ -mediated potentiation in ␣1 GlyRs.
Neuronal expressed ␣1
W170S GlyRs were insensitive to Zn 2؉ -mediated potentiation The above results have shown that ␣1 W170S -containing GlyRs lacked sensitivity to Zn 2ϩ -mediated potentiation in a recombinant expression system. However, the differential protein expression profiles between HEK293T cells and neurons might result in altered receptor functional characteristics in these two systems. To confirm that ␣1
W170S
-containing GlyRs are also insensitive to Zn 2ϩ -mediated potentiation when expressed in nerve cells, we overexpressed ␣1
WT or ␣1 W170S subunits in cultured cortical neurons as an endogenous expression system. Young cortical neurons mainly express ␣2 subunits, which exhibit substantially lower sensitivity to Zn 2ϩ potentiation than that of ␣1 (Lynch, 2004; Miller et al., 2005b) . In addition, ␣1-and ␣2-containing GlyRs have very distinct activation kinetics that can facilitate their biophysical isolation and thus also allow unambiguous confirmation of successful ␣1
WT or ␣1 W170S overexpression in neurons (Mangin et al., 2003; Mohammadi et al., 2003) . To establish the accuracy of this strategy, we first examined the activation kinetics of ␣1
WT and ␣1 W170S and compared them with the kinetics of ␣2-containing GlyRs expressed in HEK293T cells. ␣1
WT and ␣1
W170S GlyRs exhibit similar 10 -50% rise time (␣1 WT , 86.7 Ϯ 6.9 ms, n ϭ 8; ␣1
W170S
; 83.6 Ϯ 7.1 ms, n ϭ 8; p Ͼ 0.05) after application of 3 s pulses of 30 M glycine, whereas ␣2 receptors expressed in HEK293T cells exhibited substantially slower activation kinetics (10 -50% rise time: 243.9 Ϯ 17.3 ms, n ϭ 8, p Ͻ 0.01 compared with ␣1 WT or ␣1
; Fig. 4A-C) . In nontransfected cortical neurons, the same glycine application induced currents with activation kinetics similar to that of ␣2 receptors expressed in HEK293T cells (206.7 Ϯ 21.6 ms, n ϭ 7, p Ͼ 0.05 compared with ␣2 in HEK293T). Neurons overexpressing ␣1
WT or ␣1 W170S receptors showed GlyR activation kinetics with rise times ranging from 50 to 290 ms, indicating variable GlyR expression profiles. Therefore, only neurons that exhibited glycine currents with rise times Ͻ100 ms were included in our analysis and were considered to predominantly express ␣1
WT or ␣1 W170S GlyRs.
Neurons overexpressed with ␣1
WT showed remarkable increase in glycine-mediated currents by 0.1-10 M Zn 2ϩ (Fig.  4 D, E ; mean 10 -50% rise time: 66.4 Ϯ 8.9 ms, n ϭ 4). In contrast, Zn 2ϩ did not enhance glycine-mediated currents in neurons overexpressed with ␣1 W170S (Fig. 4 D, E ; mean 10 -50% rise time: 62.9 Ϯ 11.6 ms, n ϭ 5). These results confirm our findings, using W170S ␤ GlyRs, the same application of Zn 2ϩ only evoked inhibitory effects. Zn 2ϩ -mediated early effect was measured as the maximal potentiation of glycine-activated currents during the first 300 ms of Zn 2ϩ perfusion (C). Zn 2ϩ -mediated late effect was measured as the maximal inhibition of glycine-activated currents during the last 300 ms before Zn 2ϩ was washed out (D). C, D, Averaged dose-responses for Zn 2ϩ -mediated early and late effects on glycine-activated currents in homomeric ␣1
WT (n ϭ 6) and ␣1 W170S receptors (n ϭ 4). E, Top, Using the low Zn 2ϩ potentiation background H107N, Zn 2ϩ application induced only potentiation but no significant inhibition of glycine-activated currents in the homomeric ␣1 H170N receptors. Bottom, Zn 2ϩ -mediated potentiation was ablated in the ␣1 H170N/W170S double-mutant receptors. F, Averaged doseresponses for Zn 2ϩ -mediated modulations in ␣1 H170N (n ϭ 5) and ␣1 H170N/W170S receptors (n ϭ 16). a recombinant expression system, that the W170S mutation also abolished sensitivity of ␣1 GlyRs to Zn 2ϩ potentiation in neurons, and this may be a major causal factor of the symptoms of hyperekplexia in humans carrying this mutant allele.
Discussion
In the present study, we found that W170 was a novel Zn 2ϩ potentiation site at the N-terminal domain of the GlyR ␣1 subunit. This site was identified from patients with an autosomal recessive form of hyperekplexia exhibiting homozygote W170S missense mutation (Al-Futaisi et al., 2012) . We found the W170S mutation to cause complete ablation of sensitivity of ␣1 GlyRs to Zn 2ϩ potentiation. In contrast to previously identified missense glra1 mutations, it did not affect other basic electrophysiological properties of ␣1 GlyRs. After recombinant expression, the W170S mutation removed Zn 2ϩ potentiation and increased the sensitivity to Zn 2ϩ inhibition of current responses activated by glycine, ␤-alanine, or taurine. This substantial reduction of Zn 2ϩ -mediated potentiation was further revealed by temporally separating the positive and negative modulatory phases and by examining the W170S mutation using the H107N mutation background, which exhibits low sensitivity to Zn 2ϩ inhibition. Furthermore, abolishment of Zn 2ϩ potentiation was also observed in ␣1 W170S GlyRs expressed in neuronal cultures, indicating that the alteration of Zn 2ϩ modulation can also be observed in a native neuronal environment and might be a major causal factor of hyperekplexia in humans carrying W170S alleles.
Typically, missense mutations of glra1 identified from hyperekplexia might reduce agonist binding sensitivity, affect channel conductance, or disrupt receptor surface expression (Saul et al., 1999; Harvey et al., 2008; Chung et al., 2010) . We found that homomeric ␣1 W170S receptors had a twofold decrease in sensitivity to glycine compared with the WT receptors. However, in ␣1
W170S
␤ GlyRs, the W170S mutation exhibited no reduction in sensitivity to all tested agonists, no changes in the maximal current responses, and no change in I-V relationships, suggesting that there were no defects in the intrinsic channel properties of the GlyR and that abnormalities in these properties were unlikely to be the major cause of pathogenesis in hyperekplexia patients carrying the ␣1 170S mutation. Instead, our results demonstrated that the major alteration of ␣1 W170 was the ablated sensitivity to Zn 2ϩ -mediated potentiation and the consequently increased sensitivity to Zn 2ϩ inhibition. To our knowledge, the present study is the first demonstration of disrupted allosteric modulation of GlyRs by Zn 2ϩ as an important factor in human hyperekplexia symptoms.
Endogenous free Zn 2ϩ is concentrated in synaptic vesicles at certain synapses and is speculated to regulate synaptic transmission (Sensi et al., 2011) . The physiological role of Zn 2ϩ in synaptic transmission has been demonstrated by studies using Zn 2ϩ chelators or exogenous application of Zn 2ϩ to affect the duration and amplitude of glycinergic IPSCs (Suwa et al., 2001; Eto et al., 2007) . Selectively ablating sensitivity of ␣1 to Zn 2ϩ potentiation led to hyperekplexia-like phenotypes in transgenic mice carrying ␣1 D80A (Hirzel et al., 2006) . In line with these studies, our findings suggest that synaptic Zn 2ϩ plays a crucial role in glycinergic synaptic transmission and efficacy in human CNS.
